• The architecture of hydrogen and sulfur σ-hole interactions explain differences in the inhibitory potency of C-β-D-glucopyranosyl thiazoles, imidazoles and an N-β-D glucopyranosyl tetrazole for human liver glycogen phosphorylase and offer new insights to structure-based design 

      Kyriakis E., Karra A.G., Papaioannou O., Solovou T., Skamnaki V.T., Liggri P.G.V., Zographos S.E., Szennyes E., Bokor É., Kun S., Psarra A.-M.G., Somsák L., Leonidas D.D. (2020)
      C-Glucopyranosyl imidazoles, thiazoles, and an N-glucopyranosyl tetrazole were assessed in vitro and ex vivo for their inhibitory efficiency against isoforms of glycogen phosphorylase (GP; a validated pharmacological target ...
    • Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease 

      Katsiki N., Tentolouris N., Marakomichelakis G., Richter D., Giannoukas A., Koufaki P., Papanas N., Alexopoulos I., Anastasiadis F., Andreadis E., Andreopoulos G., Apostolidis D., Christodoulou I., Christopoulos I., Dalaberis E., Daliani H., Dimitriou G., Dimitsikoglou I., Dimoulis N., Doulgerakis D., Douloumpakas I., Drakopoulou E., Felekis T., Feloukas T., Florou S., Fragakis D., Fregidis T., Gakis P., Galanakis C., Giakoumis A., Giannes N., Galapis A., Gouveris I., Groutsis T., Grapsas V., Grigoropoulos P., Iordanidis T., Kazakos K., Kazantzi M., Kapernopoulos H., Kapetanios K., Karagianni E., Karakostas F., Karapiperis D., Karotsis A., Karsanidis A., Kasfikis F., Kourouklis S., Kourtis T., Kourtidou P., Koutsias S., Kotsogiannis S., Lampousakis I., Latsios P., Liouri I., Makrygiannis P., Matsouki W., Bakalakou K., Bakiris P., Balogianni M., Benis A., Beri V., Beroukas A., Moysidis K., Nanos E., Nikolaou A., Dubovina M., Oikonomidis N., Pangalos E., Panagoulias G., Papadopoulos S., Paraskevas G., Peroulis M., Petoumenos V., Petrogiannis S., Pournaras G., Pourou H., Prionidis M., Rigas A., Rigas S., Rigopoulos D., Sakellariou D., Sarafianos P., Svolis K., Seferou M., Sklirou V., Spais G., Stathopoulos C., Stavridou V., Stavrou I., Sfiniadakis I., Tatola V., Topalidis I., Trikkalinou A., Tsagarakis D., Tsarouchas P., Valkaniotis G., Varella M., Vasilakakou S., Vlachopoulou M., Vouzas A., Zafeiriou I., Zafeiris I., Zacharopoulou O., Zinelis D., CI-WIN Investigators (2022)
      Objective: to assess the effects of cilostazol on pain-free walking distance in PAD patients with IC at 3 and 6 months in a real world, prospective, observational study. We included 1015 PAD patients presenting with IC ...